Sanofi-aventis Announces the Creation of the "Sanofi Espoir" Corporate Foundation

Sanofi-aventisSanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced the creation of the Sanofi Espoir Corporate Foundation, dedicated to implementing health and solidarity programs worldwide.

For more than 20 years, the commitment of the sanofi-aventis Group and its employees has been exemplified in wide-ranging community actions that aim to help and provide emergency humanitarian aid, enable better access to healthcare and combat chronic illness in developing countries. Constructed with the support and competencies of partners involved in the communities, these programs are part of a long-term development approach, with the objective of providing long-term support for the most vulnerable populations.

Aiming to capitalize on existing initiatives and develop new programs, the sanofi-aventis Group decided to create this Corporate Foundation, Sanofi Espoir, which will be chaired by Jean-François Dehecq. Hence, sanofi-aventis wants, through innovative measures, to pursue its goal of helping provide healthcare access to those patients who need it most.

"We are very pleased that Jean-François Dehecq will chair the Sanofi Espoir Foundation as it will continues to support the company's values and will allow us to put into practice important measures focusing on health issues in our civilization today," declared Christopher A. Viehbacher, Chief Executive Officer of sanofi-aventis. "Health and Solidarity correspond to massive needs in terms of prevention, access and education. The Sanofi Espoir Corporate Foundation will find its strength in the engagement of all our employees."

About sanofi-aventis
Sanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions to improve the lives of everyone. Sanofi-aventis is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

Most Popular Now

Top 20 breaking World Pharma News of 2017

We are proud to announce the top 20 most popular breaking World Pharma News from 2017. Have a wonderful 2018 new(s) year filled with health, happiness, and spectacular su...

Novartis advances head-to-head superiority trials …

Novartis announced today the initiation of SURPASS, a head-to-head clinical trial of Cosentyx® (secukinumab) versus proposed biosimilar adalimumab** in ankylosing spondyl...

Diabetes drug 'significantly reverses memory loss…

A drug developed for diabetes could be used to treat Alzheimer's after scientists found it "significantly reversed memory loss" in mice through a triple method of action...

Sandoz regulatory submission for proposed biosimil…

Sandoz, a Novartis division and the global leader in biosimilar medicines, announced today that the US Food and Drug Administration (FDA) has accepted its Biologics Licen...

Zika remains a research and public health challeng…

Since 2016, when Zika was declared by the World Health Organization as a public health emergency of international concern, the virus has become established in more than 8...

Try exercise to improve memory, thinking

For patients with mild cognitive impairment, don't be surprised if your health care provider prescribes exercise rather than medication. A new guideline for medical pract...

New research paper shows that AstraZeneca has achi…

In a research paper published today by Nature Reviews Drug Discovery(1), AstraZeneca's IMED Biotech Unit documents a more than four-fold improvement in R&D productivity f...

Dirt-dwelling microbe produces potential anti-mela…

A type of soil-dwelling bacterium produces molecules that induce death in melanoma cells, research at Oregon State University shows. The molecule is a secondary metabolit...

Novartis Kisqali® received FDA Breakthrough Therap…

Novartis today announced Kisqali® (ribociclib) received US Food and Drug Administration (FDA) Breakthrough Therapy designation for initial endocrine-based treatment of pr...

FDA approves first treatment for breast cancer wit…

The U.S. Food and Drug Administration today expanded the approved use of Lynparza (olaparib tablets) to include the treatment of patients with certain types of breast can...

Berry gives boost to cervical cancer therapy

According to the Centers for Disease Control and Prevention, approximately 12,000 women in the United States are diagnosed with cervical cancer each year. One of the most...

Novartis appoints Elizabeth Barrett as Oncology He…

Novartis announced today that Elizabeth (Liz) Barrett, currently Global President Oncology at Pfizer, Inc., has been appointed CEO Novartis Oncology and a member of the E...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]